A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients With Recurrence After Radical Resection

Changsen Leng1,2,3†, Yingying Cui1,4†, Junying Chen1,2,3, Kexi Wang5, Hong Yang1,2,3*, Jing Wen1,3*, Jianhua Fu1,2,3* and Qianwen Liu1,2,3*

1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, 2 Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China, 3 Guangdong Esophageal Cancer Institute, Guangzhou, China, 4 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, 5 Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Background: Esophageal squamous cell carcinoma (ESCC) is characterized clinically by frequent recurrence, leading to a poor prognosis after radical surgery. The aim of this study was to identify a prognostic nomogram to predict the post-progression survival (PPS) of ESCC patients based on the features of primary tumor and recurrence.

Methods: A total of 234 ESCC patients who underwent recurrence after radical surgery were enrolled in this study. The independent prognostic factors screened by the univariate and multivariate Cox regression analysis were subsequently used to construct a nomogram. The predictive performance of the nomogram was evaluated with the concordance index (C-index), decision curve, and the area under the receiver operating characteristic curve (AUC) and validated in two validation cohorts. The Kaplan-Meier curves of different recurrence patterns were analyzed.

Results: The prognostic nomogram of PPS was established by integrating independent prognostic factors, including age, body mass index, number of lymph node dissection, recurrence pattern, and recurrence treatment. The nomogram demonstrated good performance, with C-index values of 0.756, 0.817, and 0.730 for the training and two validation cohorts. The 1-year AUC values were 0.773, 0.798, and 0.735, and 3-year AUC values were 0.832, 0.871, and 0.791, respectively. Furthermore, we found that patients with bone metastasis displayed the worst PPS compared to other isolated recurrence patterns.

Conclusion: We constructed a nomogram to reliably predict PPS, which would be valuable to provide individual managements for ESCC patients after radical surgery.

Keywords: esophageal squamous cell carcinoma (ESCC), recurrence, post-progression survival, nomogram, prognostic model
INTRODUCTION

Esophageal cancer (EC) ranks seventh in terms of global cancer incidence, leading to more than 540,000 deaths annually (1). EC is characterized by an unfavorable prognosis with a general 5-year overall survival (OS) rate of less than 10% (2). With the improvement of surgical techniques, the 3-year OS of nonmetastatic EC after esophagectomy has been improved to around 70% in recent years (3, 4). However, local recurrence and/or distant metastasis happened to more than 50% of EC patients within 3 years after esophagectomy (5, 6). The prognosis for recurrent EC patients after surgery is poor, and the median survival time is only 3-10 months (6). Therefore, it is urgent to find the influencing factors related to the post-progression survival (PPS) of recurrent EC after surgery.

Currently, several models have been shown to predict postoperative OS and progression-free survival (PFS) for EC by using primary tumor characteristics (7, 8). Whereas, compared to OS and PFS, the survival after relapse of EC patients may be influenced by characteristics of the primary tumor as well as the recurrence-related features, such as recurrence patterns, metastatic sites, and recurrence interval (9, 10). According to a study that investigated 193 esophageal squamous cell carcinoma (ESCC) patients with recurrence, both primary pathological TNM stage and treatment regimen after recurrence were independent prognostic factors for PPS (11). However, Su et al. have reported that only the recurrent information, including the time of recurrence, pattern of recurrence, and treatment after recurrence were independent prognostic factors for ESCC patients with recurrence after radical esophagectomy (5).

Furthermore, Parry et al. confirmed that the pattern of recurrence and the number of recurrent locations were independent prognostic factors for PPS (6). Butter et al. showed that resection margin status of the primary tumor, the number of positive lymph nodes after neoadjuvant therapy, age at recurrence, and location of recurrence were associated with PPS (12). These previous PPS-related findings, however, were based on univariate/multivariate analysis which could not accurately exhibit their proportion of contribution to the survival of EC patients with recurrence (5, 11, 13, 14). Hence, it is essential to establish a prognostic predictive system to better evaluate the PPS of individual EC patients. However, as far as we know, no relevant studies have been carried out.

ESCC is the main pathological type of EC globally (15). This study aims to integrate the primary and recurrent tumor characteristics and develop a prognostic nomogram to predict the PPS of recurrent ESCC patients after radical resection and evaluate its prognostic predictive performance.

MATERIALS AND METHODS

Study Population and Inclusion Criteria

Primary ESCC patients with recurrence after radical resection at the Department of Thoracic Surgery, Sun Yat-sen University Cancer Center from 1999 to 2016 were enrolled in this study. The key eligibility criteria included: (1) patients underwent McKeown or Ivor-Lewis esophagectomy; (2) histologically confirmed ESCC; (3) R0 resection (16); (4) initially stage IB-IVA (in accordance with the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system) (17); (5) patients with comprehensive clinical data; (6) at least 10 months of follow-up. Patients were excluded if: (1) patients had a secondary malignancy; (2) patients received neoadjuvant chemotherapy and/or radiotherapy. All eligible ESCC patients were enrolled in the training cohort. Patients were then randomly allocated in a 1:1 ratio to two validation cohorts. This study was approved by the Institutional Review Board of Sun Yat-Sen University Cancer Center with an approval batch number of SL-B2022-248-02 and was performed in line with the ethical guidelines of the 2013 Declaration of Helsinki.

Data Collection

Demographic data involving age, gender, smoking, drinking, diet, weight loss (since onset), body mass index (BMI), previous history of diabetes or hypertension, diagnostic date, and family history of tumor was incorporated into this study. Pathologic characteristics, including histological type, tumor location (upper third and middle/lower third segment of the esophagus), tumor size, tumor differentiation (well/moderately/poorly), number of lymph node dissection (LND), the number of positive lymph nodes, T-stage, N-stage, and AJCC stage, were evaluated by at least two pathologists specialized in tumor pathology. Tumor size was measured as the largest dimension of the lesion. The ratio of the number of positive lymph nodes to LND was defined as the lymph node metastasis ratio (LNR). Information of intraoperative thoracic duct ligation and postoperative anastomotic leakage was collected as well. Treatments after esophagectomy surgery were consisted of chemotherapy, radiotherapy, chemoradiotherapy, and no treatment. Recurrence treatment referred to the treatment after tumor recurrence, which included chemotherapy, radiotherapy, chemoradiotherapy, surgery, targeted therapy and/or immunotherapy, and supportive care.

Regular follow-up was carried out every 3-6 months after surgery. Recurrent information of ESCC patients containing the time to recurrence, site of recurrence, and the recurrent pattern was determined by endoscopic and/or imaging examinations, such as contrast-enhanced CT, MRI, bone scintigraphy, ultrasonography, and/or PET/CT. The biopsy was performed if those exams cannot clearly define the recurrence. The time to recurrence was defined as the time from the radical surgery to the first recurrence.

Recurrence patterns were categorized as local-regional recurrence and distant metastasis. Local-regional recurrence was defined as the recurrence in the following areas: the anastomotic stoma and the lymph nodes in the mediastinal, upper abdominal, and cervical areas. The terms “anastomotic only, cervical only, mediastinal only, and abdominal only” referred to isolated recurrence in anastomotic stoma and the lymph nodes in the mediastinal, upper abdominal, and cervical areas. “Multiple local” was defined as the recurrence in multiple local-regional areas. Distant metastasis was defined as any spread of disease beyond the local-regional recurrence. The terms “lung
only, liver only, bone only, and pleura only” referred to isolated recurrence in lung, liver, bone, and pleura. The term “other distant only” referred to isolated distant metastasis in other less common areas. “Multiple distant” was defined as the recurrence in multiple areas including distant metastases. Local-distant recurrence referred to the simultaneously observed local recurrence as well as distant metastasis, which was also classified in the distant metastasis group.

**Statistical Analysis**

In the present study, PPS was the interested endpoint and was defined as the time from the occurrence of tumor progression to the date of death or last follow-up. The Kaplan-Meier method was applied to estimate the survival of ESCC patients after disease recurrence and the survival differences were compared with a log-rank test. The optimal cutoff value for continuous variables was calculated by X-tile (Yale University, Version 3.6.1) (18). After checking the proportional hazards assumption with graphical method by using SPSS (19), the univariate Cox regression analysis was employed to select the clinicopathological and recurrent features by using “survival” and “survminer” packages in R. Next, variables were subjected to the least absolute shrinkage and selection operator (LASSO) analysis by using the “glmnet” package in R to identify better predictors. The multivariate Cox regression analysis was performed to further screen independent prognostic factors in ESCC patients. Then, a nomogram integrating these prognostic factors was constructed by using the “rms” package to predict the PPS. These prognostic factors were assigned points in proportion to their contribution to PPS. To verify its predictive accuracy, split-sample validation and the 1000 bootstrap resamples were applied for internal validation in this study (20). Calibration curves were used to assess the consistency between nomogram prediction and the actual outcome (20). The predictive performance of the nomogram was evaluated by the receiver operating characteristic (ROC) curve, the area under the ROC curve (AUC), and the concordance index (C-index) (20, 21). The clinical utility of the nomogram was evaluated with the decision curve analysis (22). References of R-packages were listed in Supplementary Table 1.

Clinicopathological characteristics differences were compared between two validation cohorts with chi-square or Fisher’s exact test according to sample size. P-values < 0.05 were considered statistically significant. All statistical analyses were conducted using R (Version 4.0.3, http://www.r-project.org) and SPSS (Version 23, IBM, New York, USA).

**RESULTS**

**Patient Clinicopathologic Characteristics**

A total of 234 eligible ESCC patients who underwent recurrence after radical esophagectomy were enrolled in this study, with a median follow-up of 47.5 months (range 10.3-154.5 months). The latest follow-up time was 31⁴, December 2021 and 110 patients died during the follow-up period. The average age of patients was 57 years (range 32-75 years), and the majority of patients were male (n = 189, 80.8%). Among them, 191 (81.6%) patients were initially diagnosed with squamous cell carcinoma in the middle or lower third of the esophagus. The median time to recurrence was 12.5 months. Of all recurrent patients, 91 (38.9%) experienced distant metastasis and 143 (61.1%) had only local-regional recurrence. Median PPS of patients with distant metastasis and local-regional recurrence were 16.9 and 27.1 months, respectively. The 1- and 3-year PPS rates of ESCC patients were 69.0% and 34.9%, respectively. The specific clinicopathologic and recurrent characteristics of patients in the training cohort (n = 234) and two validation cohorts (n = 117) are listed in Table 1. There were no significant differences between the two validation cohorts regarding the general characteristics of patients.

**Independent Prognostic Factors for PPS**

In order to account for potential prognostic factors for PPS, the univariate Cox regression analysis was carried out based on the variables involving clinicopathological and recurrent characteristics, all of which met the proportional hazard assumption. All these incorporated factors were analyzed as categorical variables. Our results indicated that age, primary tumor location, BMI, number of LND, recurrence pattern, bone metastasis, pleura metastasis, and recurrence treatment were closely associated with the PPS (Table 2, all P < 0.05). LNR (HR =1.446, P = 0.056) and time to recurrence (HR =1.667, P = 0.053) also exhibited the relevance to PPS, however, without statistically significant difference. Remarkably, PPS was not significantly affected by the primary tumor features including the tumor size, degree of tumor differentiation, T-stage, and N-stage. In addition, we analyzed the lymph node metastasis at each station after surgery, but there was no significant correlation with PPS (Supplementary Table 2). LASSO analysis selected seven key prognostic indicators: age, primary tumor location, BMI, number of LND, recurrence pattern, bone metastasis, and recurrence treatment (Figure 1). Further multivariate Cox analysis revealed that age (HR =1.612, P = 0.045), BMI (HR =0.579, P = 0.026), number of LND (HR =0.489, P < 0.001), recurrence pattern (HR = 1.564, P = 0.032), bone metastasis (HR =5.170, P < 0.001), and recurrence treatment (HR =0.364, P < 0.001) were significant and independent indicators for predicting PPS in ESCC patients (Table 2).

**Construction and Validation of a Prognostic Nomogram for PPS**

The prognostic nomogram integrating above independent prognostic factors was established to predict 1- and 3-year PPS rates in 234 ESCC patients with recurrence after surgery (Figure 2). Importantly, recurrence pattern had the greatest effect on the prognosis of PPS, followed by the recurrence treatment, number of LND, BMI, and age. We next aimed to assess the efficacy of the nomogram. Calibration curves showed that the nomogram-predicted probability of 1- and 3-year PPS was
TABLE 1 | Clinical and pathologic characteristics of ESCC patients.

| Characteristics       | Levels                      | Training cohort (n=234) | Validation cohort 1 (n=117) | Validation cohort 2 (n=117) | P-value |
|-----------------------|-----------------------------|-------------------------|----------------------------|----------------------------|---------|
| Age                   | ≤65 years                   | 202 (86.3%)             | 99 (84.6%)                 | 103 (88.0%)                | 0.568   |
|                       | >65 years                   | 32 (13.7%)              | 18 (15.4%)                 | 14 (12.0%)                 |         |
| Gender                | Male                        | 189 (80.8%)             | 98 (83.8%)                 | 91 (77.8%)                 | 0.320   |
|                       | Female                      | 45 (19.2%)              | 19 (16.2%)                 | 26 (22.2%)                 |         |
| Tumor location        | Upper third                 | 43 (18.4%)              | 21 (17.9%)                 | 22 (18.8%)                 | 1.000   |
|                       | Middle or lower third       | 191 (81.6%)             | 96 (82.2%)                 | 95 (81.2%)                 |         |
| Hypertension          | No                          | 213 (91.0%)             | 105 (87.9%)                | 108 (89.3%)                | 0.647   |
|                       | Yes                         | 21 (9.0%)               | 12 (10.3%)                 | 9 (7.7%)                   |         |
| Diabetes              | No                          | 227 (97.0%)             | 115 (98.3%)                | 112 (95.7%)                | 0.446   |
|                       | Yes                         | 7 (3.0%)                | 2 (1.7%)                   | 5 (4.3%)                   |         |
| Smoking               | No                          | 146 (62.4%)             | 71 (60.7%)                 | 77 (65.8%)                 | 0.587   |
|                       | Yes                         | 75 (33.6%)              | 41 (34.9%)                 | 40 (34.2%)                 |         |
| Family tumor history  | No                          | 192 (82.1%)             | 93 (79.5%)                 | 93 (79.5%)                 | 0.394   |
|                       | Yes                         | 42 (17.9%)              | 24 (20.5%)                 | 24 (20.5%)                 |         |
| Diet                  | Normal                      | 88 (37.6%)              | 46 (39.3%)                 | 42 (35.9%)                 | 0.716   |
|                       | Semi-liquid                 | 126 (53.8%)             | 60 (51.3%)                 | 66 (56.4%)                 |         |
|                       | Fluids                      | 20 (8.5%)               | 11 (9.4%)                  | 9 (7.7%)                   |         |
| Weight loss           | ≤2.5 kg                     | 176 (75.2%)             | 87 (74.4%)                 | 89 (76.1%)                 | 0.880   |
|                       | >2.5 kg                     | 58 (24.8%)              | 30 (25.6%)                 | 28 (23.9%)                 |         |
| BMI                   | ≤18.5 kg/m²                 | 40 (17.1%)              | 24 (20.5%)                 | 16 (13.7%)                 | 0.224   |
|                       | >18.5 kg/m²                 | 194 (82.9%)             | 93 (80.3%)                 | 101 (86.3%)                |         |
| Diagnostic date       | Before 2010                 | 94 (40.2%)              | 47 (40.2%)                 | 47 (40.2%)                 | 1.000   |
|                       | After 2010                  | 140 (59.8%)             | 70 (59.8%)                 | 53 (45.8%)                 |         |
| Thoracic duct ligation| No                          | 116 (49.6%)             | 57 (48.7%)                 | 58 (49.6%)                 | 0.896   |
|                       | Yes                         | 118 (50.4%)             | 60 (51.3%)                 | 58 (50.4%)                 |         |
| Anastomotic leakage   | No                          | 199 (85.0%)             | 103 (88.0%)                | 96 (82.1%)                 | 0.271   |
|                       | Yes                         | 35 (15.0%)              | 21 (17.9%)                 | 21 (17.9%)                 |         |
| Differentiation       | Well                         | 49 (20.9%)              | 27 (23.1%)                 | 22 (18.8%)                 | 0.130   |
|                       | Moderately                  | 130 (55.6%)             | 69 (59.0%)                 | 61 (52.1%)                 |         |
|                       | Poorly                      | 55 (23.5%)              | 21 (17.9%)                 | 34 (29.1%)                 |         |
| T stage               | T1b                         | 13 (5.6%)               | 6 (5.1%)                   | 7 (6.0%)                   | 0.182   |
|                       | T2                          | 39 (16.7%)              | 14 (12.0%)                 | 25 (21.4%)                 |         |
|                       | T3                          | 178 (76.1%)             | 94 (80.3%)                 | 84 (71.8%)                 |         |
|                       | T4a                         | 2 (0.9%)                | 1 (0.9%)                   | 1 (0.9%)                   |         |
|                       | T4b                         | 2 (0.9%)                | 1 (0.9%)                   | 1 (0.9%)                   |         |
| N stage               | N0                          | 75 (32.1%)              | 33 (28.2%)                 | 42 (35.9%)                 | 0.502   |
|                       | N1                          | 88 (37.6%)              | 48 (41.0%)                 | 40 (34.2%)                 |         |
|                       | N2                          | 52 (22.2%)              | 25 (21.4%)                 | 27 (23.1%)                 |         |
|                       | N3                          | 19 (8.1%)               | 11 (9.4%)                  | 8 (6.8%)                   |         |
| AJCC stage            | IA                          | 8 (3.4%)                | 3 (2.6%)                   | 5 (4.3%)                   | 0.374   |
|                       | IIA                         | 31 (13.2%)              | 12 (10.3%)                 | 19 (16.2%)                 |         |
|                       | IIB                         | 42 (17.9%)              | 22 (18.8%)                 | 20 (17.1%)                 |         |
|                       | IIIA                        | 15 (6.4%)               | 5 (4.3%)                   | 10 (8.5%)                  |         |
|                       | IIIB                        | 117 (50.0%)             | 62 (53.0%)                 | 55 (47.0%)                 |         |
|                       | IVA                         | 21 (9.0%)               | 13 (11.1%)                 | 8 (6.8%)                   |         |
| Tumor size            | ≤2.0 cm                     | 32 (13.7%)              | 13 (11.1%)                 | 19 (16.2%)                 | 0.341   |
|                       | >2.0 cm                     | 202 (86.3%)             | 104 (88.9%)                | 98 (83.8%)                 |         |
| Number of LND         | ≤10                         | 28 (12.0%)              | 13 (11.1%)                 | 15 (12.8%)                 | 0.647   |
|                       | >10, ≤18                    | 58 (24.8%)              | 32 (27.4%)                 | 26 (22.2%)                 |         |
|                       | >18                         | 148 (63.2%)             | 72 (61.5%)                 | 76 (65.0%)                 |         |
| LNR                   | ≤0.07                       | 131 (56.0%)             | 63 (53.8%)                 | 66 (58.1%)                 | 0.598   |
|                       | >0.07                       | 103 (44.0%)             | 54 (46.2%)                 | 49 (41.9%)                 |         |
| Treatment after surgery| No                          | 164 (70.1%)             | 78 (66.7%)                 | 86 (73.5%)                 | 0.325   |
|                       | CT                          | 53 (22.6%)              | 31 (26.5%)                 | 22 (18.8%)                 |         |
|                       | RT                          | 6 (2.6%)                | 4 (3.4%)                   | 2 (1.7%)                   |         |
|                       | CRT                         | 11 (4.7%)               | 4 (3.4%)                   | 7 (6.0%)                   |         |
| Time to recurrence    | ≤6.2 months                 | 40 (17.1%)              | 25 (21.4%)                 | 15 (12.8%)                 | 0.118   |
|                       | >6.2 months                 | 194 (82.9%)             | 92 (78.6%)                 | 102 (87.2%)                |         |
| Recurrence pattern    | Local-regional              | 143 (61.1%)             | 76 (65.0%)                 | 67 (57.3%)                 | 0.283   |
|                       | Distant metastasis          | 91 (38.9%)              | 41 (35.0%)                 | 50 (42.7%)                 |         |
| Lung only             | No                          | 215 (91.9%)             | 106 (90.6%)                | 109 (93.2%)                | 0.632   |

(Continued)
TABLE 1 | Continued

| Characteristics | Levels | Training cohort (n=234) | Validation cohort 1 (n=117) | Validation cohort 2 (n=117) | P-value |
|-----------------|--------|------------------------|-----------------------------|-----------------------------|---------|
| Liver only      | Yes    | 19 (8.1%)              | 11 (9.4%)                   | 8 (6.8%)                    | 0.767   |
|                 | No     | 222 (94.9%)            | 112 (95.7%)                 | 110 (94.0%)                 |         |
| Bone only       | Yes    | 12 (5.1%)              | 5 (4.3%)                    | 7 (6.0%)                    |         |
|                 | No     | 225 (96.2%)            | 114 (97.4%)                 | 111 (94.9%)                 | 0.499   |
| Pleura only     | Yes    | 9 (3.8%)               | 3 (2.6%)                    | 6 (5.1%)                    |         |
|                 | No     | 230 (98.3%)            | 116 (99.1%)                 | 114 (97.4%)                 | 0.622   |
| Other distant   | Yes    | 4 (1.7%)               | 1 (0.9%)                    | 3 (2.6%)                    |         |
|                 | No     | 224 (95.7%)            | 112 (95.7%)                 | 112 (95.7%)                 | 1.000   |
| Multiple distant| Yes    | 10 (4.3%)              | 5 (4.3%)                    | 5 (4.3%)                    |         |
|                 | No     | 225 (96.2%)            | 113 (96.6%)                 | 112 (95.7%)                 | 1.000   |
| Local Distant   | Yes    | 9 (3.8%)               | 4 (3.4%)                    | 5 (4.3%)                    |         |
|                 | No     | 206 (88.0%)            | 105 (89.7%)                 | 101 (86.3%)                 | 0.546   |
| Anastomotic only| Yes    | 11 (4.7%)              | 5 (4.3%)                    | 6 (5.1%)                    |         |
|                 | No     | 223 (95.3%)            | 112 (95.7%)                 | 111 (94.9%)                 | 1.000   |
| Cervical only   | Yes    | 177 (75.6%)            | 89 (76.1%)                  | 88 (75.2%)                  | 1.000   |
|                 | No     | 57 (24.4%)             | 28 (23.9%)                  | 29 (24.8%)                  |         |
| Mediastinal only| Yes    | 187 (79.9%)            | 91 (77.8%)                  | 96 (82.1%)                  | 0.514   |
|                 | No     | 47 (20.1%)             | 26 (22.2%)                  | 21 (17.9%)                  |         |
| Abdominal only  | Yes    | 229 (97.9%)            | 115 (98.3%)                 | 114 (97.4%)                 | 1.000   |
|                 | No     | 5 (2.1%)               | 2 (1.7%)                    | 3 (2.6%)                    |         |
| Multiple local  | Yes    | 211 (90.2%)            | 102 (87.2%)                 | 109 (93.2%)                 | 0.188   |
|                 | No     | 23 (9.8%)              | 15 (12.8%)                  | 8 (6.8%)                    |         |
| Recurrence treatment | Yes | 62 (26.5%)             | 34 (29.1%)                  | 34 (29.1%)                  | 0.459   |
|                 | No     | 172 (73.5%)            | 83 (70.9%)                  | 89 (76.1%)                  |         |
| RT              | Yes    | 18 (7.7%)              | 9 (7.7%)                    | 9 (7.7%)                    |         |
|                 | No     | 68 (29.1%)             | 34 (29.1%)                  | 34 (29.1%)                  |         |
| CT              | Yes    | 9 (3.8%)               | 4 (3.4%)                    | 5 (4.3%)                    |         |
|                 | No     | 62 (26.5%)             | 27 (23.1%)                  | 35 (29.9%)                  |         |
| Surgery         | Yes    | 15 (6.4%)              | 9 (7.7%)                    | 6 (5.1%)                    |         |

AJCC, American Joint Committee on Cancer; BMI, body mass index; LND, lymph node dissection; LNR, lymph node metastasis ratio; RT, radiotherapy; CT, chemotherapy; CRT, chemoradiotherapy; TI, targeted therapy and/or immunotherapy.

highly consistent with the actual outcome in both training and validation cohorts (Figure 3). C-indexes of the nomogram in the training and two validation cohorts were 0.756 (0.733-0.779), 0.817 (0.791-0.843), and 0.730 (0.693-0.767), respectively (Table 3). C-index was 0.733 in the bootstrapping validation (Bootstrap = 1000). Furthermore, time-dependent ROC curves were shown in Figure 4 and the 1- and 3-year AUC values in the training cohort were 0.773 and 0.832, demonstrating the satisfied predictive performance of the nomogram. Similar results (0.798 and 0.735 for 1-year AUC; 0.871 and 0.791 for 3-year AUC) were observed in two validation cohorts, which further confirmed the good reliability of the nomogram. Decision curve analysis displayed the clinical utility of the nomogram (Figure 5).

Based on the nomogram, each individual was assigned a total risk score and was then classified into the low- and high-risk subgroup according to the median value. As shown by the Kaplan-Meier curves, high-risk patients exhibited indeed significantly worse prognosis compared to patients in the low-risk group, which was subsequently demonstrated in two validation cohorts as well (Figures 6A–C, all P < 0.001). In the training cohort, age > 65 years, BMI ≤ 18.8 kg/m², less number of LND, and distant metastasis subgroups presented significantly poorer PPS outcomes as compared to age ≤ 65 years, BMI > 18.8 kg/m², more number of LND, and local-regional recurrence (Figures 6D–G, all P < 0.05), which was consistent with the result of the nomogram. Moreover, we found that among various treatments after recurrence, patients receiving targeted therapy and/or immunotherapy exhibited the best prognosis, followed by chemoradiotherapy, surgery, chemotherapy alone, radiotherapy alone, and supportive care (Figure 6H, P < 0.05).

Together, these data indicate that our nomogram provides an accurate and reliable method for predicting the PPS.

Progression Pattern and PPS

Next, we analyzed whether the different progression patterns had distinct influences on the PPS. For isolated distant metastasis, bone only metastasis displayed a significantly worse prognosis as compared to lung only and liver only metastasis (Figures 7A, B, all P < 0.01). Pleura only metastasis had similar results as bone only metastasis showing a poorer survival outcome than lung only metastasis (Figure 7C, P < 0.01) and liver only metastasis (Figure 7D, P = 0.12). No statistically significant difference emerged between bone only and pleura only metastasis (Figure 7E). Furthermore, patients in lung only metastasis and liver only metastasis subgroups had similar PPS probability (Figure 7F). For local recurrence, no significant difference of PPS was observed in terms of different isolated recurrent sites, including the anastomotic stoma and the lymph nodes in the mediastinal, abdominal, and cervical areas (Figures 7G–L).
TABLE 2 | Independent prognostic factors for PPS.

| Characteristics       | Levels                  | n (%) | Univariate analysis | Multivariate analysis |
|-----------------------|-------------------------|-------|---------------------|-----------------------|
|                       |                         |       | HR                  | 95% CI                | P-value  | HR                  | 95% CI                | P-value   |
|                       |                         |       |                     |                       |          |                     |                       |           |
| Age                   | ≤65 years               | 202 (86.3%) | 1.723               | 1.088-2.731           | 0.020    | 1.612               | 1.010-2.573           | 0.045     |
|                       | >65 years               | 32 (13.7%)  | 1.142               | 0.730-1.786           | 0.561    | 1.489               | 0.850-2.610           | 0.164     |
| Gender                | Male                    | 189 (80.8%) | 1.202               | 0.644-2.245           | 0.564    |                     |                       |           |
|                       | Female                  | 45 (19.2%)  | 0.642               | 0.158-2.605           | 0.536    |                     |                       |           |
| Tumor location        | Upper third             | 43 (18.4%)  | 1.730               | 1.003-2.985           | 0.049    | 1.489               | 0.850-2.610           | 0.164     |
|                       | Middle or lower third   | 191 (81.6%) |                     |                       |          |                     |                       |           |
| Hypertension          | No                      | 213 (91.0%) | 1.042               | 0.710-1.528           | 0.385    |                     |                       |           |
|                       | Yes                     | 146 (62.4%) | 1.153               | 0.781-1.703           | 0.473    |                     |                       |           |
| Diabetes              | No                      | 227 (97.0%) |                     |                       |          |                     |                       |           |
|                       | Yes                     | 7 (3.0%)    | 0.642               | 0.158-2.605           | 0.536    |                     |                       |           |
| Smoking               | No                      | 88 (37.6%)  | 1.042               | 0.710-1.528           | 0.385    |                     |                       |           |
|                       | Yes                     | 146 (62.4%) | 1.153               | 0.781-1.703           | 0.473    |                     |                       |           |
| Drinking              | No                      | 149 (63.7%) | 1.079               | 0.658-1.770           | 0.763    |                     |                       |           |
|                       | Yes                     | 85 (36.3%)  | 0.876               | 0.544-1.411           | 0.586    |                     |                       |           |
| Family tumor history  | No                      | 192 (82.1%) | 1.079               | 0.658-1.770           | 0.763    |                     |                       |           |
|                       | Yes                     | 42 (17.9%)  | 0.876               | 0.544-1.411           | 0.586    |                     |                       |           |
| Diet                  | Normal                  | 88 (37.6%)  | 1.052               | 0.780-1.418           | 0.741    |                     |                       |           |
|                       | Semi-liquid             | 128 (53.8%) |                     |                       |          |                     |                       |           |
|                       | Fluids                  | 20 (8.5%)   |                     |                       |          |                     |                       |           |
| Weight loss           | ≤2.5 kg                 | 176 (75.2%) | 0.876               | 0.544-1.411           | 0.586    |                     |                       |           |
|                       | >2.5 kg                 | 58 (24.8%)  |                     |                       |          |                     |                       |           |
| BMI                   | ≤18.8 kg/m²             | 40 (17.1%)  | 0.548               | 0.346-0.869           | 0.011    | 0.579               | 0.358-0.936           | 0.026     |
|                       | >18.8 kg/m²             | 194 (82.9%) |                     |                       |          |                     |                       |           |
| Diagnostic date       | Before 2010             | 94 (40.2%)  | 0.827               | 0.567-1.207           | 0.326    |                     |                       |           |
|                       | After 2010              | 140 (59.8%) |                     |                       |          |                     |                       |           |
| Thoracic duct ligation| No                      | 116 (49.6%) | 1.019               | 0.701-1.482           | 0.922    |                     |                       |           |
|                       | Yes                     | 118 (50.4%) | 1.019               | 0.701-1.482           | 0.922    |                     |                       |           |
| Anastomotic leakage   | No                      | 199 (85.0%) | 1.048               | 0.597-1.840           | 0.869    |                     |                       |           |
|                       | Yes                     | 35 (15.0%)  | 1.048               | 0.597-1.840           | 0.869    |                     |                       |           |
| Differentiation       | Well                    | 49 (20.9%)  | 0.951               | 0.718-1.260           | 0.729    |                     |                       |           |
|                       | Moderately              | 130 (55.6%) |                     |                       |          |                     |                       |           |
|                       | Poorly                  | 55 (23.5%)  |                     |                       |          |                     |                       |           |
| T stage               | T1b                     | 13 (5.6%)   | 1.038               | 0.745-1.447           | 0.824    |                     |                       |           |
|                       | T2                      | 39 (16.7%)  |                     |                       |          |                     |                       |           |
|                       | T3                      | 178 (76.1%) |                     |                       |          |                     |                       |           |
|                       | T4a                     | 2 (0.9%)    |                     |                       |          |                     |                       |           |
|                       | T4b                     | 2 (0.9%)    |                     |                       |          |                     |                       |           |
| N stage               | N0                      | 75 (32.1%)  | 0.978               | 0.792-1.207           | 0.833    |                     |                       |           |
|                       | N1                      | 88 (37.6%)  |                     |                       |          |                     |                       |           |
|                       | N2                      | 52 (22.2%)  |                     |                       |          |                     |                       |           |
|                       | N3                      | 19 (8.1%)   |                     |                       |          |                     |                       |           |
| AJCC stage            | IB                      | 8 (3.4%)    | 0.992               | 0.867-1.136           | 0.910    |                     |                       |           |
|                       | IIa                     | 31 (13.2%)  |                     |                       |          |                     |                       |           |
|                       | IIb                     | 42 (17.9%)  |                     |                       |          |                     |                       |           |
|                       | IIa                     | 15 (6.4%)   |                     |                       |          |                     |                       |           |
|                       | IIb                     | 117 (50.0%) |                     |                       |          |                     |                       |           |
|                       | NA                      | 21 (9.0%)   |                     |                       |          |                     |                       |           |
| Tumor size            | ≤2.0 cm                 | 32 (13.7%)  | 1.237               | 0.693-2.207           | 0.472    |                     |                       |           |
|                       | >2.0 cm                 | 202 (86.3%) |                     |                       |          |                     |                       |           |
| Number of LND         | ≤10                     | 28 (12.0%)  | 0.493               | 0.384-0.634           | <0.001   | 0.489               | 0.381-0.626           | <0.001    |
|                       | >10, ≤18                | 58 (24.8%)  |                     |                       |          |                     |                       |           |
|                       | >18                     | 148 (63.2%) |                     |                       |          |                     |                       |           |
| LNR                   | ≤0.07                   | 131 (66.0%) | 1.446               | 0.991-2.108           | 0.066    |                     |                       |           |
|                       | >0.07                   | 103 (44.0%) |                     |                       |          |                     |                       |           |
| Treatment after surgery| No                     | 164 (70.1%) | 0.907               | 0.702-1.171           | 0.452    |                     |                       |           |
|                       | CT                      | 53 (22.6%)  |                     |                       |          |                     |                       |           |
|                       | RT                      | 6 (2.6%)    |                     |                       |          |                     |                       |           |
|                       | CRT                     | 11 (4.7%)   |                     |                       |          |                     |                       |           |
| Time to recurrence    | ≤6.2 months             | 40 (17.1%)  | 1.667               | 0.993-2.801           | 0.053    |                     |                       |           |
|                       | >6.2 months             | 194 (82.9%) |                     |                       |          |                     |                       |           |
DISCUSSION

Recurrence was often encountered after radical resection of ESCC and greatly affected the prognosis of patients (23). Unlike the effect of predicting OS and PFS (7, 8), we found that TNM staging of primary tumor was not significantly associated with PPS in univariate analysis, suggesting that TNM staging was not effective in predicting PPS in ESCC patients. Similar to our conclusions, many studies on PPS of other cancer types suggested that the TNM staging system was less useful to predict the PPS prognosis (24, 25). Therefore, it is of practical

TABLE 2 | Continued

| Characteristics | Levels | n (%) | PPS |
|-----------------|--------|-------|-----|
|                 |        |       | Univariate analysis | Multivariate analysis |
|                 |        |       | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Recurrence pattern | Local-regional | 143 (61.1%) | 1.726 | 1.181-2.522 | 0.005 | 1.564 | 1.040-2.352 | 0.032 |
|                  | Distant metastasis | 91 (38.9%) | 0.977 | 0.494-1.935 | 0.948 |
| Lung only | No | 215 (91.9%) | 0.957 | 0.420-2.181 | 0.917 |
|              | Yes | 19 (8.1%) | 12 (5.1%) | 1.564 | 1.040-2.352 | 0.032 |
| Liver only | No | 222 (94.9%) | 7.556 | 3.540-16.130 | <0.001 | 5.170 | 2.307-11.585 | <0.001 |
|              | Yes | 9 (3.8%) | 230 (98.3%) | 3.767 | 1.182-12.012 | 0.025 |
| Pleura only | No | 244 (96.7%) | 1.630 | 0.713-3.725 | 0.247 |
|              | Yes | 10 (4.3%) | 9 (3.8%) | 1.144 | 0.421-3.108 | 0.792 |
| Other distant only | No | 225 (96.2%) | 1.280 | 0.729-2.248 | 0.391 |
|              | Yes | 9 (3.8%) | 28 (12.0%) | 0.371 | 0.091-1.505 | 0.165 |
| Multiple distant | No | 225 (96.2%) | 0.809 | 0.521-1.258 | 0.347 |
|              | Yes | 9 (3.8%) | 11 (4.7%) | 0.692 | 0.422-1.136 | 0.146 |
| Local Distant | No | 206 (88.0%) | 0.592 | 0.083-4.251 | 0.603 |
|              | Yes | 226 (96.2%) | 0.977 | 0.494-1.935 | 0.948 |
| Anastomotic only | No | 223 (96.3%) | 1.564 | 1.040-2.352 | 0.032 |
|              | Yes | 11 (4.7%) | 223 (96.3%) | 3.767 | 1.182-12.012 | 0.025 |
| Cervical only | No | 177 (75.6%) | 1.630 | 0.713-3.725 | 0.247 |
|              | Yes | 57 (24.4%) | 187 (79.9%) | 1.280 | 0.729-2.248 | 0.391 |
| Mediastinal only | No | 187 (79.9%) | 0.809 | 0.521-1.258 | 0.347 |
|               | Yes | 47 (20.1%) | 187 (79.9%) | 0.692 | 0.422-1.136 | 0.146 |
| Abdominal only | No | 229 (97.9%) | 0.592 | 0.083-4.251 | 0.603 |
|               | Yes | 5 (2.1%) | 229 (97.9%) | 0.977 | 0.494-1.935 | 0.948 |
| Multiple local | No | 211 (90.2%) | 1.082 | 0.592-1.978 | 0.797 |
|               | Yes | 23 (9.8%) | 211 (90.2%) | 0.363 | 0.244-0.540 | <0.001 |
| Recurrence treatment | No | 62 (26.5%) | 0.363 | 0.244-0.540 | <0.001 | 0.364 | 0.241-0.551 | <0.001 |
|               | Yes | 173 (73.5%) | 0.977 | 0.494-1.935 | 0.948 |
| RT | 18 (7.7%) | 172 (73.5%) | 0.692 | 0.422-1.136 | 0.146 |
| CT | 68 (29.1%) | 18 (7.7%) | 68 (29.1%) | 0.977 | 0.494-1.935 | 0.948 |
| Surgery | 9 (3.8%) | 68 (29.1%) | 0.692 | 0.422-1.136 | 0.146 |
| CRT | 62 (26.5%) | 9 (3.8%) | 62 (26.5%) | 0.977 | 0.494-1.935 | 0.948 |
| TI | 15 (6.4%) | 62 (26.5%) | 0.977 | 0.494-1.935 | 0.948 |

PPS, post-progression survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; BMI, body mass index; LND, lymph node dissection; LNR, lymph node metastasis ratio; RT, radiotherapy; CT, chemotherapy; CRT, chemoradiotherapy; TI, targeted therapy and/or immunotherapy.

FIGURE 1 | Feature selection using the least absolute shrinkage and selection operator (LASSO) Cox regression model. LASSO coefficient profiles of variables against the log lambda sequence for PPS (A) and tuning parameter (λ) selection in the LASSO model for PPS (B).
significance to establish a nomogram for these patients. In this study, we explored the prognostic indicators for PPS based on clinicopathological characteristics and recurrent information of ESCC patients, after which a novel nomogram was established for the first time to predict the PPS of ESCC patients with recurrence after radical surgery. We demonstrated that the nomogram integrating age, BMI, the number of LND, recurrence pattern, and recurrence treatment was an accurate and reliable predictive approach to PPS in ESCC patients. Compared to previous PPS-related univariate/multivariate analysis (5, 6, 11, 12), our nomogram could predict PPS with the quantitative score.

Age was demonstrated predictive of OS and PFS of ESCC patients (26–28). Elderly patients were reported less benefit from intensive anti-cancer therapy (29). Butter et al. showed that older age was a risk factor for post recurrence survival of EC patients who underwent potentially curative esophagectomy (12). In line with this, advanced age was an unfavorable prognosis indicator of PPS in our study as well, especially for patients over 65 years of age, who were accompanied by an aging immune system (30), the poor functional reserve of multiple organ systems, and increased susceptibility to stimulation (31). With stratified analysis, Sugawara et al. revealed that elderly ESCC patients with low BMI had significantly poorer OS than patients with high BMI (32). Remarkably, EC patients with the recurrence were characterized by a lower BMI as compared to patients without the recurrence (33). Beyond that, low BMI was also found to be associated with worse PPS of ESCC patients in our work. BMI may affect prognosis by reflecting the nutritional status of ESCC patients (34). These results further highlight the importance of BMI in the prognosis of ESCC patients.

LND is known as a significant prognosis indicator of EC patients, however, the optimal number of resected lymph nodes remains controversial (35, 36). Based on the Surveillance Epidemiology and End Results database, it has been shown that with the number of LND increasing, the OS and cancer-specific survival were significantly increased in 4882 EC patients and patients receiving 30 or more LND had the lowest mortality rate.
when compared to other groups (37). National Comprehensive Cancer Network guidelines (Version 2.2022) recommended that at least 15 lymph nodes should be dissected for patients with EC, whether they received preoperative chemoradiotherapy or not. From the point of PPS, we found ESCC patients accepting more than 18 LND exhibited better clinical outcomes than patients in other groups, providing novel evidence of the contribution of LND and its exact quantity to the prognosis of ESCC.

Several retrospective studies confirmed the importance of salvage treatment for EC patients with recurrence. In the multivariate analysis of prognostic factors in 190 ESCC patients with recurrence after esophagectomy, Su et al. showed that treatment after recurrence was an independent prognostic factor for survival (5). Rodriguez-Camacho et al. also found that EC patients who received chemotherapy, radiotherapy, or a combination of both displayed a higher post-recurrence survival rate than palliative care (6.5 months vs. 2.9 months). However, the results were not statistically significant due to the limited sample size (33). Furthermore, Ni et al. reported that compared with those only treated with radiotherapy, the median PPS time of ESCC patients increased from 16.2 to 23.2 months after receiving chemoradiotherapy (11). Zhang et al. and Ni et al. put forward the specific salvage radiation dose and suggested that ≥60 Gy could effectively improve the prognosis of recurrent EC patients (11, 38). In the present study, we proved the effectiveness of salvage treatment for ESCC patients, and the targeted therapy and/or immunotherapy was found to be the optimal treatment for ESCC patients after recurrence.

The recurrence pattern was also part of the nomogram. Previously, it was demonstrated that local-regional recurrence and distant metastasis resulted in significantly different survival outcomes in ESCC after radical resection, and distant metastasis indicated poorer PPS (5), which was consistent with our results. In addition, we also analyzed features of subgroups of distant metastasis and local-regional recurrence. Among isolated distant metastases, lung only metastasis was the most common type, followed by liver only metastasis and bone only metastasis, which was identical with previous reports (5). Among them, bone only metastasis showed the greatest impact on PPS, which was worse than lung and liver metastasis. Indeed, various studies have demonstrated that bone metastasis in EC led to poorer PPS, as compared to liver or lung metastasis (39, 40).

### TABLE 3 | The C-index and AUC values in the training and validation cohorts.

| Cohort               | C-index 1-year | AUC 1-year | C-index 3-year | AUC 3-year |
|----------------------|---------------|------------|---------------|------------|
| Training cohort      | 0.756 (0.733-0.779) | 0.773 | 0.730 (0.693-0.767) | 0.791 |
| Validation cohort 1  | 0.817 (0.791-0.843) | 0.798 | 0.730 (0.693-0.767) | 0.791 |
| Validation cohort 2  | 0.730 (0.693-0.767) | 0.735 | 0.730 (0.693-0.767) | 0.791 |

PPS, post-progression survival; C-index, concordance index; AUC, area under receiver operating characteristic curve.

### FIGURE 4 | The receiver operating characteristic (ROC) curves for predicting post-progression survival of ESCC patients at 1- and 3-year in the training cohort (A, D), validation cohort 1 (B, E), and validation cohort 2 (C, F), respectively.
Beyond that, Zhang et al. reported that bone metastasis was particularly likely to happen to male EC patients in their study (39). For the local-regional recurrence, recurrences at various local-regional sites did not show different effects on PPS but were generally better than distant metastasis.

This study has important guiding value for clinicians, who can use these findings to assess the PPS among patients with ESCC following radical resection and provide patients with individual recommendations and measures. For instance, for patients with high-risk factors, such as older age, intensive follow-up should be recommended. Patients need to be reminded to pay attention to BMI and strengthened their postoperative nutrition. Furthermore, it also reminds the surgeon that an appropriate number of lymph nodes should be removed during the operation. More vigilance should be raised when distant metastasis occurs in postoperative patients, especially bone metastasis. Active treatment is necessary and can significantly improve prognosis. Therefore, the results of this study can be used to predict survival after the progression of

**FIGURE 5** | Decision curve analysis (DCA) for the nomogram model in the training cohort (A), validation cohort 1 (B), and validation cohort 2 (C) for PPS. The red lines represent the DCA of the nomogram.

**FIGURE 6** | The Kaplan-Meier curves for the risk subgroups of ESCC patients. Patients were stratified by the prognostic score of the nomogram in the training cohort (A), validation cohort 1 (B), and validation cohort 2 (C). Stratification of patients by significant characteristics after multivariate analysis in the training cohort: age (D), BMI (E), number of LND (F), recurrence pattern (G), and recurrence treatment (H).
ESCC and are potential of benefit to the intervention of decision-making. However, several limitations need to be pointed out in this study. First, the sample size was still relatively small. We expect to enroll more patients and even verify in prospective studies in the future. In addition, although the prognostic model showed good fitness after validation, we should recognize that our validation cohorts were derived from the training cohort, so it would be better to further validate our nomogram in more independent cohorts.

In conclusion, we have developed a nomogram to predict PPS in ESCC patients with recurrence after radical surgery. Validation by training and validation cohorts showed that the nomogram had a strong predictive ability for PPS. In addition, we also compared the PPS of different recurrence patterns. The establishment of this nomogram could provide new insights into the individualized ESCC patients with recurrence.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The Institutional Review Board of Sun Yat-Sen University Cancer Center approved this study. The patients/participants...
provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

QL, JF, and JW conceptualized and designed the study. QL, CL, YC, JC, KW, HY, and JW collected and assembled the data. QL, CL, and YC analyzed and interpreted the data. All authors have contributed to the article and approved the submitted version.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3332/caac.21660

2. Huang FL, Yu SJ. Esophageal Cancer: Risk Factors, Genetic Association, and Treatment. Asian J Surg (2018) 41(3):210–5. doi: 10.1016/j.asjsur.2016.10.005

3. Kroll D, Borbely YM, Dislich B, Haltmeier T, Malinka T, Biel D, et al. Favourable Long-Term Survival of Patients With Esophageal Cancer Treated With Extended Transhiatal Esophagogastrectomy Combined With En Bloc Lymphadenectomy: Results From a Retrospective Observational Cohort Study. BMC Surg (2020) 20(1):197. doi: 10.1186/s12893-020-00885-x

4. Li B, Zhang Y, Miao L, Ma L, Luo X, Zhang Y, et al. Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial. J Thorac Oncol (2021) 16(2):310–7. doi: 10.1016/j.jtho.2020.10.157

5. Su XD, Zhang DK, Zhang X, Lin P, Long H, Rong TH. Prognostic Factors in Patients With Recurrence After Complete Resection of Esophageal Squamous Cell Carcinoma. J Thorac Dis (2014) 6(7):949–57. doi: 10.3978/j.issn.2072-1439.2014.07.14

6. Parry K, Visser E, van Rossum PS, Mohammad NH, Ruurda JP, van Hillegersberg R. Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagogastrectomy With Curative Intent. Ann Surg Oncol (2015) 22(3 Suppl 3):S1292–300. doi: 10.1245/s10434-015-4840-5

7. Lennini R, Diaz Vico T, Trumbull DA, Attwood K, Spaulding AC, Ellis EF, et al. Prognostic Models for Stage I-Ii Esophagogastric Carcinoma: A Comparison Between Existing Calculators. J Gastrointest Oncol (2021) 12(5):1963–72. doi: 10.21037/jgo-2021-05-113

8. Zhan Z, Huang X, Gu T, Chen Z, Gan L, Zhu B, et al. Predicting Individual Survival After Curative Esophagectomy for Squamous Cell Carcinoma of Esophagus. Gastroenterol Res Pract (2021) 2021:559718. doi: 10.1155/2021/559718

9. Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, et al. Comparison of 3 Pacifica-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. JAMA Netw Open (2022) 5(2):e220120. doi: 10.1001/jamanetworkopen.2022.0120

10. Qiu MJ, Yang SL, Wang MM, Li YN, Jiang X, Huang ZZ, et al. Prognostic Evaluation of Esophageal Cancer Patients With Stages I-II. Aging (Albany NY) (2020) 12(1):14736–53. doi: 10.18632/aging.105332

11. Ni W, Yang L, Deng W, Xiao Z, Zhou Z, Zhang H, et al. Patterns of Recurrence After Surgery and Efficacy of Salvage Therapy After Recurrence in Patients With Thoracic Esophageal Squamous Cell Carcinoma. BMC Cancer (2020) 20(1):144. doi: 10.1186/s12885-020-06622-0

12. Butter R, Lagarde SM, van Oijen MGH, Anderegg MCJ, Gisbertz SS, Meijer SL, et al. Treatment Strategies in Recurrent Esophageal or Junctional Cancer. Dis Esophagus (2017) 30(9):1–9. doi: 10.1093/dote/dox082

13. Kanie Y, Okamura A, Maruyama S, Sakamoto K, Fujiwara D, Kanamori J, et al. Clinical Significance of Serum Squamous Cell Carcinoma Antigen for Patients With Recurrent Esophageal Squamous Cell Carcinoma. Ann Surg Oncol (2021) 28(12):7990–6. doi: 10.1245/s10434-021-09945-5

14. Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, et al. What Are the Factors That Predict Outcome at Relapse After Previous Esophagectomy and Adjuvant Therapy in High-Risk Esophageal Cancer? Curr Oncol (2010) 17(6):46–51. doi: 10.3747/co.v17i6.561

15. Collaborators GBDOC. The Global, Regional, and National Burden of Oesophageal Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol (2020) 5(6):582–97. doi: 10.1016/S2468-1253(20)30007-8

16. Hermanek P, Wittekind C. Residual Tumor (R) Classification and Prognosis. Semin Surg Oncol (1994) 10(1):12–20. doi: 10.1002/ssu.2980100105

17. Rice TW, Patil DT, Blackstone EH. 8th Edition Aajc/Uacc Sizing of Cancers for Esophagus and Esophagogastric Junction: Application to Clinical Practice. Ann Cardiothorac Surg (2017) 6(2):119–30. doi: 10.1016/j.acs.2017.03.134

18. Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clin Cancer Res (2004) 10(21):7252–9. doi: 10.1158/1078-0432.CCR-04-0713

19. Dey T, Mulkerjee A, Chakraborty S. A Practical Overview and Reporting Purposes. J Thorac Dis (2020) 12(5):1963. doi: 10.21037/jtho.2020.10.157

20. Pencina MJ, D’Agostino RB. Evaluating Discrimination of Risk Prediction Models: The C Statistic. JAMA (2015) 314(10):1063–4. doi: 10.1001/ jama.2015.11082

21. Vickers AJ, Van Calster B, Steyerberg EW. Net Benefit Approaches to the Evaluation of Prediction Models, Molecular Markers, and Diagnostic Tests. BMJ (2016) 352:i6. doi: 10.1136/bmj.i6

22. Kanda M, Koike M, Shimizu D, Tanaka C, Hattori N, Hayashi M, et al. Characteristics Associated With Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Ann Surg Oncol (2020) 27(9):3195–205. doi: 10.1245/s10434-020-08433-6

23. Fang Q, Yang R, Chen D, Fei R, Chen P, Deng K, et al. A Novel Nomogram to Predict Prolonged Survival After Hepatectomy in Repeat Recurrent Hepatocellular Carcinoma. Front Oncol (2021) 11:646638. doi: 10.3389/ frontonc.2021.646638

24. He C, Sun S, Zhang Y, Lin X, Li S. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. Front Oncol (2020) 10:51564. doi: 10.3389/fonc.2020.01564

25. Wu J, Yang J, Lin X, Lin L, Jiang W, Xie C. Survival Outcomes for Patients With Four Treatments in Stages I-Ii Esophageal Squamous Cell Carcinoma: A Seer Analysis. Transl Cancer Res (2021) 10(5):2144–52. doi: 10.21037/tcr-20-2995

26. Li J, Hu Y, Qiu R, Li J, Li Y, He M, et al. Survival Risk Prediction Model for Patients With Pt1-3 N0M0 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy With Two-Field Lymphadenectomy for Therapeutic Purposes. J Cardiothorac Surg (2021) 16(1):121. doi: 10.1186/s13019-021-01503-0

FUNDING

This work was supported by grant from the China Postdoctoral Science Foundation (No. 2021M693655).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.925685/full#supplementary-material
28. Yan L, Zhao Q, Liu L, Jin N, Wang S, Zhan X. Expression of Sirt1 and Survivin Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma. *Med (Baltimore)* (2020) 99(34):e21645. doi: 10.1097/MD.0000000000021645

29. Wang L, Wang X, Ren X, Han C, Xiao Z, Zhu S, et al. Age Plays an Important Role in the Decision of Definitive Concurrent Chemoradiotherapy (Cct) for Esophageal Squamous Cell Carcinoma (Escc): A Propensity-Score Matched Analysis of Multicenter Data (3jecrog R-02a). *Transl Cancer Res* (2021) 10 (6):2932–43. doi: 10.21037/tcr-21-505

30. Al-Mansour Z, Pang L, Bathini V. Novel Cancer Therapeutics in Geriatrics: What Is Unique to the Aging Patient? *Drugs Aging* (2019) 36(1):1–11. doi: 10.1007/s40266-018-0619-2

31. Colloca G, Corsonello A, Marzetti E, Balducci L, Landi F, Extermann M, et al. Treating Cancer in Older and Oldest Old Patients. *Curr Pharm Des* (2015) 21 (13):1699–705. doi: 10.2174/1381612821666150130122536

32. Sugawara K, Yamashita H, Okumura Y, Yagi K, Aikou S, Seto Y. Age-Dependent Survival Impact of Body Mass Index in Patients With Oesophageal Squamous Cell Carcinoma. *Eur J Surg Oncol* (2020) 46(10 Pt A):1948–55. doi: 10.1016/j.ejso.2020.05.012

33. Rodriguez-Camacho E, Pita-Fernandez S, Pertega-Diaz S, Lopez-Calvino B, Seoane-Pillado T. Characteristics and Pattern of Recurrence After Curative Surgery in Oesophageal Cancer. *Rev Esp Enferm Dig* (2015) 107(9):539–46. doi: 10.17235/reed.2015.3748/2015

34. Miyazaki T, Sakai M, Solida M, Tanaka N, Yokobori T, Motegi Y, et al. Prognostic Significance of Inflammatory and Nutritional Parameters in Patients With Esophageal Cancer. *Anticancer Res* (2016) 36(12):6557–62. doi: 10.21873/anticancerres.11259

35. Wang Z, Mao Y, Gao S, Li Y, Tan L, Daiko H, et al. Lymph Node Dissection and Recurrent Laryngeal Nerve Protection in Minimally Invasive Esophagectomy. *Ann N Y Acad Sci* (2020) 1481(1):20–9. doi: 10.1111/nyas.14427

36. Soeno T, Harada H, Hosoda K, Mieno H, Ema A, Ushiku H, et al. Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy. *Ann Surg Oncol* (2019) 26(4):996–1004. doi: 10.1245/s10434-019-07190-5

37. Groth SS, Virmig BA, Whitson BA, DeFor TE, Li ZZ, Tuttle TM, et al. Determination of the Minimum Number of Lymph Nodes to Examine to Maximize Survival in Patients With Esophageal Carcinoma: Data From the Surveillance Epidemiology and End Results Database. *J Thorac Cardiovasc Surg* (2010) 139(3):612–20. doi: 10.1016/j.jtcvs.2009.07.017

38. Zhang J, Peng F, Li N, Liu Y, Xu Y, Zhou L, et al. Salvage Concurrent Radio-Chemotherapy for Post-Operative Local Recurrence of Squamous-Cell Esophageal Cancer. *Radiat Oncol* (2012) 7:93. doi: 10.1186/1748-717X-7-93

39. Zhang S, Guo J, Zhang H, Li H, Hassan MOO, Zhang L. Metastasis Pattern and Prognosis in Men With Esophageal Cancer Patients: A Seer-Based Study. *Med (Baltimore)* (2021) 100(25):e26496. doi: 10.1097/MD.0000000000026496

40. Qi G, Zhang H, Wang F, Zheng Y, Wang Y. Patterns of Metastasis and Prognosis of Elderly Esophageal Squamous Cell Carcinoma Patients in Stage Ivb: A Population-Based Study. *Transl Cancer Res* (2021) 10(11):4591–600. doi: 10.21037/tcr-21-1128

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Leng, Cui, Chen, Wang, Yang, Fu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.